The clinical spectrum of limb girdle muscular dystrophy. A survey in the Netherlands by Kooj, A.J. (Anneke) et al.
Brain (1996), 119, 1471-1480
The clinical spectrum of limb girdle muscular
dystrophy
A survey in the Netherlands
A. J. van der Kooi,1 P. G. Barth,1 H. F. M. Busch,9 R. de Haan,2 H. B. Ginjaar,3 A. J. van Essen,5
L. J. M. A. van Hooff,10 C. J. Howeler,7 F. G. I. Jennekens," P. Jongen,12 H. J. G. H. Oosterhuis,6
G. W. A. M. Padberg,12 F. Spaans,8 A. R. Wintzen,4 J. H. J. Wokke,11 E. Bakker,3
G. J. B. van Ommen,3 P. A. Bolhuis1 and M. de Visser1
Departments of ^Neurology and 2Clinical Epidemiology
and Biostatistics, Academic Medical Centre, Amsterdam,
the ^Department of Human Genetics, University of Leiden,
the ^Department of Neurology, Academic Hospital Leiden,
the ''Department of Medical Genetics, University of
Groningen, the 6Department of Neurology, Academic
Hospital Groningen, the Departments of1Neurology and
8Clinical Neurophysiology, Academic Hospital Maastricht,
the 9 Department of Neurology, Academic Hospital Dijkzigt,
Rotterdam, the ^Department of Neurology, St Franciscus
Hospital, Roosendaal, the " Department of Neurology,
Academic Hospital Utrecht and the ^Department of
Neurology, Academic Hospital Nijmegen, The Netherlands
Correspondence to: Dr A. J. van der Kooi, Department of
Neurology, Academic Medical Centre, University of
Amsterdam, PO Box 22700, 1100 DE Amsterdam, The
Netherlands
Summary
A cross-sectional study was performed in the Netherlands
to define the clinical characteristics of the various
subtypes within the broad and heterogeneous entity of limb
girdle muscular dystrophy (LGMD). An attempt was made
to include all known cases of LGMD in the Netherlands. Out
of the reported 200 patients, 105 who fulfilled strictly
defined criteria were included. Forty-nine patients, mostly
suffering from dystrophinopathies and facioscapulohumeral
muscular dystrophy, appeared to be misdiagnosed. Thirty-
four cases were sporadic, 42 patients came from autosomal
recessive and 29 from autosomal dominant families. The
estimated prevalence of LGMD in the Netherlands was at
least 8.1X]O~6. The clinical features of the autosomal
recessive and sporadic cases were indistinguishable from
those of the autosomal dominant patients, although calf
hypertrophy was seen more frequently, and the course of the
disease was more severe in autosomal recessive and sporadic
cases. The pectoralis, iliopsoas and gluteal muscles, hip
adductors and hamstrings were the most affected muscles.
Distal muscle involvement occurred late in the course of
the disease. Facial weakness was a rare phenomenon. The
severity of the clinical picture was correlated with a
deteriorating lung function. All autosomal dominantly
inherited cases showed a mild course, although in two
families life-expectancy was reduced because of concomitant
cardiac involvement.
Keywords: limb girdle muscular dystrophy; prevalence; a-sarcoglycan; linkage analysis
Abbreviations: CK = creatine kinase; FSHD = facioscapulohumeral dystrophy; FVC = forced vital capacity; LGMD =
limb girdle muscular dystrophy
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Introduction
Limb girdle muscular dystrophy has long been a controversial
entity (Bradley, 1979; Ten Houten, 1979; Walton and Gardner-
Medwin, 1981; Shields, 1994). After careful exclusion of all
possible genetically and clinically different diseases which
also manifest with limb girdle weakness, a repository of
cases remains that fits the diagnosis of LGMD (Bushby,
1994). Recent linkage studies demonstrated an association
between LGMD and various chromosomal loci (Beckmann
et al, 1991; Ben Othmane et al., 1992; Speer et al., 1992;
Bashir et al., 1994; Roberds et al., 1994; Passos-Bueno,
1996) and thereby reaffirmed the existence of LGMD. Partial
or complete deficiency of various dystrophin-associated
proteins has been demonstrated in patients with autosomal
recessive muscular dystrophy, both as a primary feature and
as a secondary event (Azibi et al., 1993; Roberds et al.,
1994; Bbnneman et al., 1995; Lim et al, 1995; Noguchi
et al., 1995; Worton, 1995). On a recent workshop, a proposal
for a new nomenclature based on gene search results has
been made (Bushby and Beckmann, 1995).
LGMD1 designates chromosome 5q-linked autosomal
dominant LGMD as described by Gilchrist. Characteristics
of this phenotype are late-onset limb girdle weakness,
dysarthria and facial weakness (Gilchrist et al., 1988; Speer
et al., 1992). Other chromosomal localizations for autosomal
dominantly inherited LGMD are as yet unknown. There is
mostly a relatively benign course (De Coster et al., 1974;
Bethlem and Wijngaarden, 1976; Chutkow et al., 1986;
Gilchrist and Leshner, 1986; Marconi et al., 1991; Somer
et al., 1991).
LGMD2A denotes the chromosome 15q-linked autosomal
recessive disorder encountered in families on Reunion Island
(Beckmann et al., 1991). Subsequently several different
mutations have been identified in the gene encoding for
the proteolytic enzyme calpain 3 (Richard et al., 1995). In
the Amish population, linkage to chromosome 15 has also
been found in affected families in northern Indiana, first
described by Jackson (Jackson and Carey, 1961; Jackson and
Strehler, 1968), whereas in the southern Indiana families
linkage was excluded (Young et al., 1992; Allamand et al.,
1995). The phenotype of the chromosome 15 linked form
shows childhood onset progressive limb girdle weakness
without calf hypertrophy (Fardeau et al, 1996).
LGMD2B refers to the chromosome 2pl3.3-linked subtype
(Bashir et al, 1994; Passos-Bueno et al, 1995), that has its
onset mostly after the age of 15 years and usually shows
slow progression.
Another subset of patients with autosomal recessive
inheritance, early onset and rapid progression, known as
Duchenne-like severe childhood autosomal recessive
muscular dystrophy (SCARMD1), was first reported from
Tunisia (Ben Hamida et al, 1983). Linkage analysis has
mapped the gene to the pericentromeric region of the long
arm of chromosome 13ql2 (Ben Othmane et al, 1992). This
form is now called LGMD2C. Marked inter- and intrafamilial
variability as regards the age of onset and the course of the
disease was noted. In some patients secondary a-sarcoglycan
deficiency has been demonstrated (Azibi et al, 1993).
Recently the gene encoding the dystrophin-associated
glycoprotein y-dystroglycan (35DAG) has been mapped to
13q 12, and mutations in this gene were found (Noguchi
et al., 1995).
Limb girdle muscular dystrophy with primary a-
sarcoglycan deficiency, previously called SCARMD2, has
been linked to chromosome 17 and now constitutes LGMD2D
(Roberds et al., 1994). A variety of mutations has been found
in families with a broad range of clinical presentations and
intrafamilial variability, and they may be associated with a
range of a-sarcoglycan staining patterns (Matsumura et al,
1992; Fardeau et al, 1993; Roberds et al, 1994; Romero
et al, 1994; Zatz et al, 1994; Hayashi et al, 1995; Kawai
et al., 1995; Passos-Bueno et al, 1995; Ljunggren et al,
1995; Piccolo et al, 1995).
Limb girdle muscular dystrophy in the old order Amish
of southern Indiana is linked to markers on chromosome 4q,
and constitutes LGMD2E. The gene for the P-sarcoglycan
component of the dystrophin-associated-glycoprotein
complex has been mapped to 4ql2, and has been found to
be defective in these patients, and in one other patient
(Bonneman et al., 1995; Lim et al, 1995).
So far, most of our knowledge about LGMD has been
derived from large families, that have been suitable for
linkage analysis. Detailed genotype-phenotype correlations
have not been made as yet, due to extreme variability in
severity which could be associated with any of the identified
genetic localizations (Jackson and Carey, 1961; Jackson and
Strehler, 1968; Ben Hamida et al, 1983; Bashir et al, 1994).
At present little is known about prevalence rates, and about
the natural history of the disease.
We undertook a study on a large group of LGMD patients
collected from all neuromuscular centres in the Netherlands.
The aims of this cross-sectional study were (i) to estimate
the prevalence of LGMD in the Netherlands, (ii) to make an
inventory of the clinical spectrum of LGMD, and (iii) to
identify factors associated with the severity of the disease.
Methods
Patients
The survey was performed in 1993 and 1994 on 200 patients
in whom a tentative diagnosis of LGMD had been made
between 1980 and 1993. They were recruited from the files
of all (seven) neuromuscular centres of the university hospitals
in the Netherlands, and from our national patients' association
('Vereniging Spierziekten Nederland'). Patients were
evaluated in two stages to determine whether they met our
inclusion and exclusion criteria. In the first stage the records
of all patients were reviewed. After this initial selection,
patients who met our criteria and had given informed consent
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to participate in the study, were personally examined. The
second selection was based on the results of this clinical
examination and of the review of muscle biopsy specimens.
The inclusion criteria consisted of the following: person of
either gender with progressive, more or less symmetric limb
girdle weakness, in whom ancillary investigations [including
serum creatine kinase (CK) activity, EMG and muscle biopsy]
were compatible with a primary myogenic disorder. Patients
were excluded if another disorder manifesting with limb girdle
weakness was present, including metabolic and inflammatory
myopathies, dystrophinopathies, spinal muscular atrophies,
congenital myopathies/dystrophies, facioscapulo humeral
dystrophy (FSHD), Emery-Dreifuss muscular dystrophy or
rigid spine syndrome. Therefore, exclusion criteria were
congenital onset, ptosis or weakness of external ocular
muscles, skin rash compatible with dermatomyositis, sensory
abnormalities, severe facial weakness, distal weakness more
severe than proximal; and the presence of florid active
denervation, ragged red fibres or numerous extensive cellular
infiltrates on muscle biopsy, or glycogen or fat accumulation
within the muscle fibres. Abnormalities in dystrophin analysis
of muscle biopsy specimens, deletions or duplications within
the dystrophin gene (Xp21), the presence of Turner karyotype
or X-autosome translocations were additional exclusion
criteria.
Seventy-four individuals were excluded during the first
evaluation for the following reasons: 11 were deceased; in
four insufficient information was available; two lived abroad;
three addresses were unknown; 26 refused to enter the study;
in 28 another diagnosis was made: 11 were diagnosed as
having dystrophinopathy (10 patients with Becker and one
manifesting carrier; dystrophin analysis of muscle tissue was
carried out in 37 patients), one polymyositis, 11 FSHD, one
spinal muscular atrophy, one autosomal dominantly inherited
scapulo-ilio-peroneal atrophy with cardiopathy (Jennekens
et al., 1975), and three congenital myopathies or muscular
dystrophies.
At the entry of the study 126 subjects were included. They
were examined clinically and their muscle biopsies were
reviewed. A tentative subdivision was made into autosomal
recessive, sporadic and autosomal dominant cases. Autosomal
recessive inheritance was considered likely when con-
sanguinity was proven or when more than one affected
sibling, including at least one girl, was present, and the
parents were healthy. Sporadic cases might be either
autosomal recessive or new mutations of an autosomal
dominant form. Autosomal dominant inheritance was
considered likely when affected persons in two or more
generations were present, and the possibility of X-linked
dystrophinopathy was excluded by means of Xp21 screening,
and/or dystrophin analysis.
Neurological evaluation
The patients were examined by one of the authors (A.J.K.)
using a standardized protocol. Seven patients were seen at
home, and all other patients were examined in our hospital.
The neurological history included questions about the age of
onset, the first symptoms of weakness and progression of the
disease to other muscle groups.
Muscle strength was assessed (Kendall et al., 1971),
using the British Medical Research Council scale (Medical
Research Council, 1943). Thirty-three muscle groups were
examined bilaterally. The facial muscles were graded on a
three-point scale (0 = severely affected; 1 = mildly affected;
2 = normal). Reflexes were assessed on a five-point scale
(0 = absent; 1 = diminished; 2 = normal; 3 = increased;
4 = clonus). The presence of contractures in eight joints on
both sides [shoulders, elbows, wrists, hands (fingerflexors),
hips, knees and ankles] were graded on a three-point scale
(0 = absent; 1 = mild; 2 = severe). The presence of
scoliosis, atrophy and hypertrophy were graded on a two-
point scale (0 = absent; 1 = present).
Seventy-four healthy family members over the age of 18
years (who also had given their informed consent), were
examined as well.
Other investigations
All patients completed a brief questionnaire focusing on
respiratory symptoms; i.e. breathlessness, fatigue, sleep-
related symptoms, and headache upon waking. Forced vital
capacity (FVC) was measured in 84 patients in the sitting
position with a hand-held spirometer. It was registered as
a percentage of the normal value related to age, height
and gender.
All patients were assigned a functional grade based on a
scale designed by Vignos et al. (1963), and modified by
Brooke et al. (1981). This scale is subdivided in two parts:
one for shoulders and arms, varying from 1 = patients being
able to fully abduct their arms, to 6 = loss of useful function
of arms and hands; and one for hips and legs, varying from
1 = patients being able to walk and climb stairs without
assistance, to 10 = confinement to bed.
Genealogical investigations, extending to five generations
of ancestors, were performed in a pilot study that included
the first 15 families, excluding those with autosomal dominant
inheritance. Genealogical investigations were also carried out
in other families in which, on the basis of family history,
consanguinity was suspected. Serum CK activity was assessed
in all patients and in the majority of their parents and siblings.
Extensive cardiological investigations were performed in
all patients. These results will be described in a separate paper.
Muscle biopsy specimens of all patients were re-evaluated
by one of the authors (M.de V.) to rule out other causes of limb
girdle syndrome as mentioned above. They were classified
as either myopathic, dystrophic or neurogenic. Myopathic
changes consisted of variation in muscle fibre size, an increase
in the number of fibres with internal nuclei and fibre
splitting. Dystrophic changes included myopathic changes in
combination with degenerating and/or regenerating fibres.
Neurogenic changes comprised the presence of small angular
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fibres, staining darkly with oxidative enzymes and non-
specific esterase, or the presence of fibre-type grouping.
Immunohistochemical analysis of cc-sarcoglycan was
performed in 34 available frozen biopsy specimens.
Obligatory additional ancillary investigations consisted of
chromosomal analysis including karyotyping in all sporadic
female cases, and Xp21 screening in all sporadic cases. Both
immunohistochemical and immunobiochemical analyses of
dystrophin in frozen muscle biopsy specimens was performed
in all sporadic male cases, in all families in which only males
were affected, and in the majority of sporadic female patients.
Acid maltase assay and ischaemic forearm test were
undertaken when history or (reported) muscle biopsy
abnormalities raised suspicion of a metabolic myopathy.
Statistical analysis
We described the relationship between disease duration and
patterns of muscle weakness in relative frequencies.
Furthermore we assessed the association between FVC and
severity of disease in terms of a relative risk with 95%
confidence limits. Relative risk expresses how much more
likely severe disease is among patients with a marked
reduction of pulmonary capacity than among patients with a
normal capacity. Cut-off value for the functional leg score
was 5, because we considered the loss of independent walking
as an important indicator for the progression of the disease.
The same applied to the cut-off value for the functional arm
score of 2, reflecting the loss of ability to raise the arms
above the head. The cut-off point for FVC was set at 70%
of the normal value.
of neurogenic muscle biopsy changes another two patients
were diagnosed as having spinal muscular atrophy and
therefore excluded (this diagnosis was affirmed by DNA
analysis showing deletions on the spinal muscular atrophy
locus on chromosome 5).
Finally, 105 patients, all residents of the Netherlands,
entered our study for further analysis. Ninety-seven patients
were of Caucasian origin, five came from Morocco, one from
Turkey, one from Peru and one was of Indian descent. Forty-
two autosomal recessive cases originated from 24 multiplex
or consanguineous families; 34 were sporadic patients; 29
individuals came from 10 autosomal dominant families.
Nineteen family members (12 in the autosomal recessive
families, and seven in the autosomal dominant families) were
reported to have the same disorder, but they refused to
participate in the study. The prevalence was estimated on
January 1, 1993. The number of inhabitants in the Netherlands
at that time was 15 239 182. Therefore, the prevalence of
all LGMD cases amounted at least to 8.1 X10"6 [(105+19)/
15 239 182] individuals, and of the autosomal recessive and
sporadic cases at least to 5.7X 10"6 [(42 + 34+12)/15 239 182).
Genealogical investigations were performed in 19 families.
In seven of these, in which the family history was suggestive,
consanguinity was found. In three other families genealogical
investigations were extended because of common surnames
in the ancestors in the fifth generation. In all three,
consanguinity was confirmed: in the sixth, sixth and 10th
generation, respectively. Although two other families of
Moroccan origin reported consanguinity as well, no data for
genealogical investigations were available.
Linkage analysis
Most families were too small for linkage analysis. Linkage
analysis was performed in two large autosomal dominant
families with cardiac involvement to evaluate the possibility
of linkage to chromosome 5q.
Results
The study population comprised 126 patients whose records
had met our inclusion and exclusion criteria. After clinical
examination and reviewing of the muscle biopsy specimens
during the second evaluation another 21 patients had to be
excluded. In one patient a diagnosis of mitochondrial
myopathy seemed more likely on the basis of ptosis and
external ophthalmoplegia, six were diagnosed as FSHD
because of severe facial weakness or asymmetric scapulo-
humeroperoneal weakness (this diagnosis was affirmed by
DNA analysis in four and supported in one). Three individuals
were thought to have congenital myopathy, one rigid spine
syndrome, one Emery-Dreifuss muscular dystrophy, and
one Miyoshi (distal) myopathy. Six patients had atypical
distribution of weakness, with distal leg muscles more or to
the same extent affected as the proximal muscles. Because
Clinical characteristics of the patients with
LGMD
The bar graph (see Fig. 1) shows the distribution of muscle
weakness at the time of examination. The autosomal recessive
and sporadic cases are considered as one group (see
Discussion) and are compared with the autosomal dominant
patients. The majority of patients had atrophy and weakness
of the proximal muscles of upper and lower limbs, particularly
when symptoms had been present for >10 years (data not
shown). Weakness was most frequently observed in the
pectoralis, iliopsoas, gluteal, hip adductor, and the hamstring
muscles. Mild facial weakness was seen in only four patients
with a mean disease duration of 23.5 years (range 22-27
years). Distal weakness occurred late in the course of the
disease. Wrist and finger extensor muscles, tibialis anterior
and toe extensor muscles were the most frequently involved
distal muscles. No clear distinctions are present between the
different subtypes.
Despite severe weakness, no patient lost hand function nor
was bedridden. Long leg braces were used by only one patient.
The knee and biceps jerks disappeared first in most patients,
whereas the ankle reflexes were often relatively spared. In
13 patients, however, ankle jerks disappeared at an early
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Fig. 1 Muscle involvement on 105 LGMD patients. The bar graph shows the distribution of weakness
at the time of examination. The autosomal recessive and sporadic cases are considered as one group and
compared with the autosomal dominant patients. AD = autosomal dominant; AR = autosomal
recessive; spor = sporadic.
stage of the disease. Achilles tendon contractures were
observed in 59% of patients with a median disease duration
of 23 years (range 0-54 years). Scoliosis was present in
26.4% of patients with a median disease duration of 22 years
(range 4-54 years).
Eighty-four patients had no respiratory complaints, 11 had
slight breathlessness, three experienced continuous breath-
lessness, three had sleep-related problems and four required
assisted ventilation during the night. The median FVC for
all 84 patients in whom it was measured was 95.0% (range
16.9-158). The median FVC for wheelchair-bound patients
was 68.0% (range 16.9-123.8). Patients with a pronounced
reduction of FVC were more likely to have severely impaired
functional arms scores (relative risk = 4.4; 95% confidence
limits: 2.0/8.4) and leg scores (relative risk = 5.9; 95%
confidence limits: 2.6/13.4).
Subdivision into autosomal recessive, sporadic,
autosomal dominant cases (see also Table 1)
Autosomal recessive LGMD
Consanguinity was present in three families with sporadic
patients and in eight of the 21 multiplex families.
The symptoms started in the proximal leg muscles in 36
patients. Weakness of the shoulder girdle and upper arm
muscles occurred in 20 patients after a median disease
duration of 10 years (range 1-35 years). In six patients,
muscle weakness became manifest simultaneously in upper
and lower limbs. Thirty-three patients developed weakness
of the distal leg muscles in the course of the disease. In five
patients the only affected distal leg muscles were the calves.
Slight facial weakness was seen in one 22-year-old patient,
who had been wheelchair-dependent for 11 years and required
assisted ventilation during the night.
Dystrophic changes were seen in all muscle biopsy
specimens.
Three patients out of 13 in whom a-sarcoglycan screening
was performed showed a partial deficiency. One was a 19-
year-old wheelchair-dependent Moroccan girl, the other a
46-year-old Dutch woman who walked until the age of 44
years, and the third a 55-year-old man, who lost the ability
to walk at the age of 46 years.
Sporadic cases
In 32 of the 34 cases, weakness was first evident in the
proximal leg muscles. In 20 of those patients, weakness of
the shoulder girdle muscles became evident after a median
disease duration of 10 years (range 1^3 years). In two
patients, muscle weakness became manifest simultaneously
in upper and lower limbs. Late distal leg involvement was
present in 20 patients. In one patient the calf muscles were
the only affected distal leg muscles. Facial weakness was
not seen. Two patients required assisted ventilation during
the night.
Dystrophic changes were seen in the muscle biopsies of
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Table 1 The clinical characteristics of the patients with LGMD (n = 105)
Autosomal
recessive total
42 (17;25)
36 (8-66)
12 (1-57)
20 (2-52)
15
26 (8-50)
23
27
8
23.6 (1-720)
96.6 (29-158)
Sporadic total
34 (12;22)
31 (3-65)
8 (1-33)
18(1-58)
12
16(11-69)
14
20
11
21.8(1-116.3)
89.7 (16.9-126.7)
Autosomal dominant
Total (M + F)
29(12;17)
39 (30-69)
12 (3-52)
23 (0-50)
3
45 (33-47)
5
14
5
5.4 (1-34)
96.5(48.7-142.1)
Cardiac involvement
Absent
14 (4; 10)
48 (33-69)
12 (3-52)
23 (10-43)
3
45 (33^17)
3
9
3
10 (2.6-34)
102.1 (48.7-142.1)
Present
15 (8;7)
33 (30-61)
10(5-38)
22 (0-50)
0
-
2
5
2
1.3(1-8.3)
96.1 (59.4-113.6)
Number of patients (M;F)
Median age in years (range)
Median age of onset in years (range)
Median disease duration in years (range)
Number of wheelchair dependent patients
Median age of losing ambulation in years (range)
Calf hypertrophy (number of patients)
Achilles tendon contractures (number of patients)
Scoliosis (number of patients)
Median serum CK activity (times normal value)
Median FVC* (% of the normal value)
*Measured in 84 patients.
29 patients, one showed an end stage myopathy, and in four,
myopathic changes were present.
In three of the 21 muscle biopsies stained for a-
sarcoglycan, this protein was found to be completely absent.
One girl, aged 17 years, had been wheelchair-dependent for
3 years, and the other two, aged 10 and 27 years, were barely
able to walk independently.
Autosomal dominant LGMD
On the basis of the results of a cardiological investigation, a
clear distinction between autosomal dominant families with
and without cardiac involvement emerged.
Autosomal dominant LGMD without cardiac
involvement. This group consisted of 14 individuals
from eight families. Weakness started in the proximal
muscles of the legs in 13 patients, the shoulder girdle and
proximal upper limb muscles being affected in 10 patients
after a median disease duration of 13 years (range 5-36
years). In one patient, the shoulder and pelvic girdle muscles
were simultaneously involved. Seven patients showed distal
leg muscle weakness. Slight facial muscle weakness was
seen in one patient.
Dystrophic muscle biopsies were seen in 12 patients, and
two patients showed myopathic changes.
Autosomal dominant LGMD with cardiac
involvement. This group consisted of 15 patients from
two families. Symptoms at onset were due to muscle weakness
of the proximal legs. In three patients, shoulder and proximal
arm muscles became affected as well after a median disease
duration of 21 years (range 10-25 years). Distal leg weakness
was observed in seven patients. Slight facial muscle weakness
was seen in two. Seven patients had very mild contractures
of their elbows.
Four patients showed dystrophic muscle biopsy changes.
Cardiological abnormalities included a variety of
dysrhythmias and conduction disturbances, such as atrio-
ventricular block and bradycardia. In some, cardiological
involvement gave rise to syncopal attacks and even sudden
cardiac death.
Congestive cardiomyopathy was present in two individuals.
Chromosomal linkage studies excluded the locus on
chromosome 5q (these data will be the subject of a
separate paper).
Family members
In the autosomal recessive families 20 additional family
members, and 33 family members of the sporadic cases were
examined, but no muscle weakness was found. Serum CK
activity, estimated in 36 individuals, was normal in 31. Five
had a slightly raised serum CK activity ranging from 1.2 to
1.8 times the upper limit.
Examination of 21 additional family members of the
autosomal dominant cases yielded three individuals who were
presumed to have the disorder because they complained of
decreased muscle strength, and because of the presence of a
slightly elevated serum CK activity (1.2 to 2.5 times the
upper limit), although there was no muscle weakness. The
serum CK activity of the other 18 family members was
normal, except for one individual who had a slightly elevated
serum CK activity (1.2 times the upper limit).
Discussion
In this cross-sectional study we have attempted to include
all known cases of LGMD in the Netherlands. Initially, 200
patients were reported with a tentative diagnosis of LGMD".
After subjecting the records of all patients to clearly defined
inclusion and exclusion criteria, 126 patients remained. These
individuals were examined clinically, and their muscle biopsy
specimens were reviewed. After this second screening,
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another 21 patients had to be excluded, leaving only 105
patients for further analysis. Therefore, we stress the
importance of thorough investigations to rule out other
diseases before accepting a diagnosis of LGMD. The
introduction of new techniques such as dystrophin analysis,
and Xp21, chromosome 4q and chromosome 5 screening are
extremely helpful to exclude dystrophinopathies, FSHD and
spinal muscular atrophy, respectively. A total of 28 patients
suffering from these conditions were initially misdiagnosed
as LGMD.
In a world survey of population frequencies (Emery, 1991),
the prevalence and incidence rates for mainly adult onset
cases of LGMD were estimated at 20-40 X10"6. In a study
by Yates and Emery (1985) the prevalence of adult onset
cases was 7X10"6 at the most. Because of our well-defined
diagnostic criteria and the demographic advantages of the
Netherlands for ascertaining the majority of LGMD cases,
probably a more reliable prevalence could be established. In
our study the prevalence of cases with childhood and adult
onset was at least 8.1 X10"6, which is lower than previously
reported. We presume that the previously mentioned
prevalence rates have been artificially inflated by a number
of neurogenic and myopathic disorders with a limb girdle
distribution of weakness mimicking LGMD. On the other
hand, our prevalence rate may be an underestimate because
our study comprised a larger number of females than males,
and presumably a number of male LGMD patients in the
files of the neuromuscular centres, in whom no dystrophin
analysis has been performed, have been misclassified as
Duchenne or Becker muscular dystrophy.
Although it has been reported that in LGMD weakness
may begin in either upper or lower limb muscles (Walton,
1993; Bushby, 1994), in our patients weakness started either
in the proximal leg muscles or simultaneously in upper and
lower limbs. All patients reported to have onset of weakness
in the shoulder girdle muscles were diagnosed as FSHD,
because they had either facial weakness, asymmetric
weakness, only slightly elevated serum CK activities, or a
family history consistent with autosomal dominant
inheritance. In two of our patients with scapular onset limb
girdle weakness, in whom a diagnosis of FSHD was proven
by DNA analysis, only a trace of facial weakness was
demonstrable, occurring in a late stage of the disease.
The muscle disorder in these patients resembles a recently
described scapular onset muscular dystrophy without apparent
facial involvement that had possible allelism with FSHD
(Jardine el al, 1994).
Forty-two patients came from autosomal recessive families,
34 cases were sporadic and 29 were autosomal dominant
cases. The clinical features of the different genotypes,
including the distribution of weakness, the presence of
contractures and reflexes, were indistinguishable. Only calf
hypertrophy was more frequently seen in autosomal recessive
and sporadic cases. Likewise, the clinical picture was more
severe as compared with the autosomal dominant cases.
Serum CK activities in our autosomal dominant families
(median 5.4 times the upper limit of normal) were lower
than those of the autosomal recessive cases (median value
23.6 times the upper limit of normal), which is line with the
literature (Bushby, 1994).
Awaiting the results of direct mutation analysis and further
immunostaining of the available muscle biopsies in our
patients, we tried to make a distinction between the different
phenotypes.
Sixteen patients of our autosomal recessive group strongly
resembled the Tunisian patients in whom linkage to
chromosome 13 was found (LGMD2C). They all showed the
features described by Ben Hamida et al. (1983), i.e. onset of
their disease before the age of 13 years, severe progression
leading to wheelchair-dependency before the age of 31
years, marked rise of serum CK activity, almost consistent
hypertrophy of the calves and dystrophic muscle biopsy
changes. Five out of 16 originated from consanguineous
Moroccan marriages.
Eighteen patients might match the description of the
chromosome 15 linked LGMD2A (Jackson and Carey, 1961;
Jackson and Strehler, 1968; Beckmann et al., 1991; Young
et al., 1992; Fardeau et al., 1996), in which the following
characteristics were found: age of onset between 3 and 30
years of age (predominantly childhood onset) with quite a
variable age of confinement to a wheelchair, dystrophic
changes on muscle biopsy and gross abnormalities of serum
enzymes particularly in the early stages. Since shoulder and
pelvic girdle muscles were reported to be affected to the
same extent (Jackson and Carey, 1961; Jackson and Strehler,
1968, Fardeau et al., 1996), especially the patients in our
study, who had had simultaneous onset of weakness in
shoulder and hip girdle muscles, might fit into this category.
The distinction between LGMD2A and LGMD2C,
however, is difficult to make because interfamilial variability
is frequent, and there is considerable overlap.
The clinical picture of the two families with onset in the
late teens and relatively slow progression, in which recently
linkage to chromosome 2 was found (LGMD2B) (Bashir
et al., 1994), has not been described in detail yet. Distal
(Miyoshi) myopathy, with onset of muscle weakness in the
gastrocnemius and soleus muscles, has been reported to be
linked to the same locus (Bejaoui et al., 1995). Interestingly,
CT scanning of LGMD2B patients showed early involvement
of the soleus, along with the abductors and the hamstring
muscles (Bushby and Beckmann, 1995). Five of our
autosomal recessive patients had limb girdle weakness and
a selective decrease in strength and atrophy of the calf
muscles. This is a remarkable finding since calf muscles are
usually among the most preserved muscles in limb girdle
muscular dystrophy (Walton and Gardner-Medwin, 1981).
Most of the sporadic cases will probably be autosomal
recessive cases, because nearly all patients had serum CK
activities that were elevated more than 10 times the normal
value, and calf hypertrophy was frequently observed.
Genealogical investigations in these particular patients do
not seem very useful, because in our pilot study consanguinity
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could only be confirmed in families in which it was already
suspected. The same considerations concerning classification
as have been made for the autosomal recessive cases can be
applied to the sporadic group. Six of the 34 patients had
atypical features. One patient, who became wheelchair-
dependent at the age of 16 years, had a slightly elevated
serum CK activity throughout all stages of the disease. His
muscle biopsy specimen revealed an end stage myopathy.
This patient might resemble the patients of the large Sudanese
kindred described by Salih et al. (1983) who had been
suffering from a severe, progressive form of muscular
dystrophy with onset between the ages of 3 and 5 years, with
dystrophic features on muscle biopsy, and a mildly elevated
(up to five times the normal value) serum CK activity. Four
patients had an only slightly elevated serum CK activity and
sole myopathic changes, without degenerating or regenerating
fibres, on muscle biopsy. Another patient showed dystrophic
changes, but had an only four times elevated serum CK
activity. The latter five may be de novo mutations of autosomal
dominant LGMD.
a-Sarcoglycan deficiency in three autosomal recessive
cases and absence in three sporadic cases, indicate that
primary and secondary oc-sarcoglycan deficiencies are
encountered in the Netherlands as well. The clinical pictures
of these patients showed great variation, as is also the case
in the reported patients (Matsumura et al., 1992; Azibi et al.,
1993; Fardeau et al., 1993; Roberds et al, 1994; Romero
etal., 1994; Zatz et al., 1994; Hayashi et al., 1995; Ljunggren
etal., 1995; Passos-Bueno etal., 1995; Piccolo etal., 1995).
Autosomal dominantly inherited LGMD was believed to
be rare (Walton and Nattrass, 1954; Jerusalem and Sieb,
1992). As yet, relatively few families have been described
with autosomal dominant LGMD, showing a wide range of
clinical features and histological findings (Schneidermann
et al, 1969; Bacon and Smith, 1971; De Coster et al., 1974;
Bethlem and Wijngaarden, 1976; Hastings et al, 1980;
Chutkow et al, 1986; Gilchrist et al, 1988; Marconi et al.,
1991; Somer et al., 1991; Miller et al., 1992). In our study,
the autosomal dominantly inherited LGMD cases encompass
28% (29 out of 105) of the LGMD patients. Most of the
reported autosomal dominant forms had a relatively late
onset, i.e. in the third or fourth decade (Bacon and Smith,
1971; De Coster et al., 1974; Aguilar et al., 1978; Chutkow
et al., 1986; Gilchrist and Leshner, 1986; Marconi et al.,
1991), although symptoms sometimes occurred in childhood
(Schneidermann et al., 1969; Bethlem and Wijngaarden,
1976; Fenichel et al., 1982; Miller et al., 1985; Panegyres
et al., 1990; Somer et al., 1991). In our families, the mean
age of onset was 23.4 years. In 15 patients the onset of
symptoms was before the age of 13 years. Calf enlargement
was observed in some cases (Aguilar et al., 1978; Panegyres
et al., 1990; Hastings et al., 1980), and, indeed, in our
families it was found in five of the 29 patients. Dysarthria
and facial weakness were distinctive features of LGMD1, but
these were not seen in our families. Linkage to chromosome 5
was excluded in our two large autosomal dominant families.
In keeping with the literature, progression of the disease was
usually mild in our patients. Only three became wheelchair-
bound after the age of 30 years. However, in two of our
autosomal dominant families, severe cardiac involvement
shortened the life-expectancy. To an extent these families
resemble autosomal dominant Emery-Dreifuss muscular
dystrophy, but the absence of early contractures and of
spinal rigidity clearly distinguishes between these disorders.
Therefore, the disorder has been recognized as a new entity
(Van der Kooi et al., 1996).
Forced vital capacity decreased with deterioration of the
clinical picture. Life expectancy is probably determined by
pulmonary function. This implies that, especially in the more
severely disabled patients, doctors should be aware of the
development of respiratory symptoms. Notably appearance
of sleep-related problems and continuous breathlessness
necessitate further investigations in order to institute timely
artificial ventilation.
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